Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

The Role of Marrow Fibrosis in the Prognosis and Treatment of Myelodysplastic Syndromes: a Single Center Retrospective Study

Emma M Groarke, MRCPI, Su Wai Maung, MRCP, MBBS, FRCPath, Karl Ewins, MRCPI, Michael Jeffers, FRCPath, Johnny McHugh, FRCPath, Ronan Desmond, MD FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2016) 128 (22): 5524.

https://doi.org/10.1182/blood.V128.22.5524.5524

Published: 2016

Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD

Blood (2016) 128 (22): 3237.

https://doi.org/10.1182/blood.V128.22.3237.3237

Published: 2016

Journal Articles

Increased p53 Expression in Patients with Therapy-Related MDS/AML Is Common and May be Associated with a Poor Prognosis

Su Wai Maung, MBBS, MRCP(UK), Niamh Strahan, MSc, Sarah O'Dowd, M.Sc, John O'Loughlin, Ronan Desmond, MD FRCPath, Johnny McHugh, FRCPath, Michael Jeffers, FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2015) 126 (23): 5245.

https://doi.org/10.1182/blood.V126.23.5245.5245

Published: 2015

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Changes in p53 Expression By Immunohistochemistry during Azacitidine Therapy in Patients with MDS Can Predict Overall Prognosis

Su Wai Maung, MBBS, MRCP(UK), Niamh Strahan, M.Sc, Philomena O'Byrne, M.Sc, Sarah O'Dowd, M.Sc, John O'Loughlin, Ronan Desmond, MD FRCPath, Johnny McHugh, FRCPath, Michael Jeffers, FRCPath, Helen Enright, MD FRCPI, FRCPath

Blood (2015) 126 (23): 2878.

https://doi.org/10.1182/blood.V126.23.2878.2878

Published: 2015

Journal Articles

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Amjad Hayat, MBBS, PhD, David O'Brien, Fiona Quinn, PhD, Fionnuala Keane, PhD, Imelda Parker, PhD, Johanna Kelly, BSc, Marzena Wieczorkowska, Gerard Crotty, MD, Maeve Leahy, MD, Helen Enright, MD, Brian Hennessy, MD, Mary Cahill, MB, Elisabeth A. Vandenberghe, MB, PhD

Blood (2012) 120 (21): 1791.

https://doi.org/10.1182/blood.V120.21.1791.1791

Published: 2012

Journal Articles

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

Su Wai Maung, MBBS, MRCP(UK), Denis O'Keeffe, MD, MRCPath, Maeve Leahy, MD, MRCPath, Hilary M O'Leary, MBBChBAO, MRCPI, MRCPath, Irfan Khan, Mary Cahill, FRCPath, Oonagh Galligan, FRCPath, Philip Murphy, MD, MRCPath, Janusz Krawczyk, MRCPI, Suzanne McPherson, MRCPI, J F Jackson, FRCPath, Mary Ryan, FRCPath, Brian Hennessy, MRCPath, Aine C Burke, MBBChBAO, MRCPI, Helen Enright, MD, Johnny McHugh, FRCPath

Blood (2011) 118 (21): 3171.

https://doi.org/10.1182/blood.V118.21.3171.3171

Published: 2011

Journal Articles

PAD Given at Relapse Is More Effective Than VAD Given as Induction Therapy - Results of a Phase II Study.

Treen C. Morris, Paul J. Kettle, Mary B. Drake, Aisleen Brunton, Gordon Cook, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather Oakervee, James D. Cavenagh

Blood (2007) 110 (11): 2724.

https://doi.org/10.1182/blood.V110.11.2724.2724

Published: 2007

Journal Articles

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients

Sherrill J. Slichter, Kathryn Davis, Helen Enright, Hayden Braine, Terry Gernsheimer, Kuo-Jang Kao, Thomas Kickler, Edward Lee, Janice McFarland, Jeffrey McCullough, Glenn Rodey, Charles A. Schiffer, Robert Woodson

Blood (2005) 105 (10): 4106–4114.

https://doi.org/10.1182/blood-2003-08-2724

Published: 2005

Journal Articles

The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells

Louise Cragg, Robert P. Hebbel, Wesley Miller, Alex Solovey, Scott Selby, Helen Enright

Blood (1998) 92 (2): 632–638.

https://doi.org/10.1182/blood.V92.2.632

Published: 1998

NARROW

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

The Role of Marrow Fibrosis in the Prognosis and Treatment of Myelodysplastic Syndromes: a Single Center Retrospective Study

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Increased p53 Expression in Patients with Therapy-Related MDS/AML Is Common and May be Associated with a Poor Prognosis

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Changes in p53 Expression By Immunohistochemistry during Azacitidine Therapy in Patients with MDS Can Predict Overall Prognosis

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Multicentre Retrospective Analysis of Rituximab Use in the Treatment of Steroid Resistant Autoimmune Haemolytic Anaemia in Ireland,

PAD Given at Relapse Is More Effective Than VAD Given as Induction Therapy - Results of a Phase II Study.

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients

The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only